A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

Table 3 Adverse events

	IM Olz, 10 mg (N=45)	IM Placebo (N=45)
Item	n (%)	n (%)	pvalue^a
TEAE	13 (28.9)	6 (13.3)	.120
ADR	9 (20.0)	4 (8.9)	.230
TEAE leading to discontinuation	0 (0.0)	0 (0.0)	———
Severe TEAE	0 (0.0)	0 (0.0)	———
Serious adverse event	0 (0.0)	0 (0.0)	———

Abbreviations: ADR= adverse drug reaction; IM Olz=intramuscular olanzapine; N= number of patients in the full analysis set; n=number of patients with ≥1 event;TEAE=treatment-emergent adverse event.
^a p value: Fisher's exact test.

ISSN: 1471-244X